Top Markets
Coin of the day
Science 37 Holdings, Inc. Science 37 Holdings, Inc.

Science 37 Holdings, Inc.

SNCE
Rangering i aksjer #11780
Science 37 Holdings, Inc. specializes in providing innovative technology... Science 37 Holdings, Inc. specializes in providing innovative technology solutions to enable flexible and decentralized clinical trials. Their central platform facilitates modern, digital approaches to clinical research by bringing together all essential parties—including patients, trial investigators, nurses, coordinators, and sponsors—to streamline processes, centralize data generation, and standardize information. Furthermore, the platform integrates specialized networks of patient communities, telemedicine-enabled investigators, mobile nursing professionals, remote coordinators, and connected health devices, all vital for orchestrating adaptable clinical studies. Its highly configurable nature means it can support nearly any phase of a clinical study and a wide range of medical indications. Beyond its direct services, the company also licenses its proprietary, cloud-based technology platform to various life science institutions. Science 37 serves a diverse client base, including major and mid-sized pharmaceutical companies, Contract Research Organizations (CROs), academic institutions, and biotechnology firms. Established in 2014, Science 37 Holdings, Inc. is headquartered in Research Triangle Park, North Carolina.
Aksjekurs
$5.75
Sist synkronisert: 2024-03-22
Markedsverdi
$659.57M
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Science 37 Holdings, Inc. (SNCE)

Kategori

EPS for Science 37 Holdings, Inc. (SNCE)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Science 37 Holdings, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Science 37 Holdings, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter